TRAW Traws Pharma, Inc.
Price Chart
Executive Summary
Traws Pharma reported Q1 2026 results with zero revenue and a net loss of $7.1M ($-0.53/share), a sharp reversal from the $21.5M net income in Q1 2025 driven by a non-cash warrant liability gain. The company's cash burn continues, with cash dropping to $3.1M at quarter-end before the April PIPE infusion. The S-3 resale registration filed 7 days ago creates massive overhang (237% of shares outstanding), and the FDA clinical hold on the lead TXM program remains unresolved. The combination of negative operating results, dilutive overhang, and regulatory uncertainty makes this a bearish filing.
Actionable Insight
The S-3 resale overhang (237% of float) will pressure the stock regardless of pipeline updates. Watch for MHRA approval on the TXM challenge trial as the next binary catalyst — approval could trigger the Series A milestone warrant exercise ($10M). Until the FDA clinical hold is resolved, the stock remains a high-risk speculative name with severe dilution overhang.
Key Facts
- Q1 2026 revenue was $0.0M vs $0.06M in Q1 2025
- Net loss of $7.1M ($-0.53/share) vs net income of $21.5M ($2.17/share) in Q1 2025
- Cash and cash equivalents fell to $3.1M at March 31, 2026 from $3.8M at December 31, 2025
- R&D expense doubled to $4.9M from $2.5M YoY as cash burn accelerated
- S-3 filed May 8, 2026 registers 35.9M shares for resale (237% of outstanding shares)
- FDA clinical hold on lead TXM program remains unresolved
- April 2026 PIPE provided $10M upfront with up to $50M in milestone-based warrants
- Shares outstanding grew to 15.15M as of May 12, 2026 from 10.16M at March 31, 2026
- Stockholders' deficit widened to -$5.3M from -$0.6M at year-end 2025
Financial Impact
Q1 2026 net loss of $7.1M; cash burn of ~$0.7M/month; $10M PIPE upfront provides runway into Q1 2027
Risk Factors
- Massive dilution from S-3 resale registration (35.9M shares, 237% of outstanding)
- FDA clinical hold on TXM program unresolved with no clear timeline
- Cash burn accelerating with R&D spend doubling YoY
- Stockholders' deficit worsening, going concern risk if milestones not met
- Milestone-based warrants may not be exercised, limiting future funding
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-061771 |
| Document: tm2614707d1_8k.htm | 0001104659-26-061771 |
| Document: 0001104659-26-061771-index-headers.html | 0001104659-26-061771 |
| Document: 0001104659-26-061771-index.html | 0001104659-26-061771 |
| Document: 0001104659-26-061771.txt | 0001104659-26-061771 |
| 8-K Data (Synthetic) | 0001104659-26-061771 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
11d ago
|
DEFA14A
| $1.46 $1.45 | ▼ −0.68% | ▼ −0.39% | $1.31 (−10.27%) |
|
May 27, 2026
13d ago
|
8-K
| $1.53 $1.42 | ▼ −7.19% | ▼ −8.40% | $1.31 (−14.38%) |
|
May 26, 2026
14d ago
|
8-K
| $1.53 $1.45 | ▼ −5.23% | ▼ −5.70% | $1.31 (−14.38%) |
|
May 22, 2026
18d ago
|
424B5
| $1.49 $1.47 | ▲ +1.34% | ▲ +3.02% | $1.31 (+12.08%) |
|
May 18, 2026
22d ago
|
EFFECT
| $1.76 $1.58 | ▲ +10.23% | ▲ +11.85% | $1.31 (+25.57%) |
|
May 15, 2026
25d ago
|
8-K
| $1.88 $1.49 | ▲ +20.74% | ▲ +21.71% | $1.31 (+30.32%) |
|
May 15, 2026
25d ago
|
Press Release
| $1.88 $1.49 | ▼ −20.74% | ▼ −21.71% | $1.31 (−30.32%) |
|
May 8, 2026
4w ago
|
S-3
| $2.02 $1.76 | ▲ +12.87% | ▲ +12.79% | $1.31 (+35.15%) |
|
May 8, 2026
4w ago
|
Press Release
| $2.18 $1.63 | ▼ −25.23% | ▼ −26.69% | $1.31 (−39.91%) |
|
Apr 15, 2026
7w ago
|
8-K
| $1.21 $1.22 | ▲ +0.83% | ▼ −0.16% | $1.31 (+8.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access